Trials / Completed
CompletedNCT00697112
Study Evaluating The Use Of Sirolimus In Recipients Of Kidney Allografts From Expanded Criteria Donors (ECD)
Surveillance Registry Of Sirolimus Use In Recipients Of Kidney Allograft From Expanded Criteria Donors (ECD)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 53 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this observational study is to examine the clinical outcomes of the use of sirolimus as base therapy in kidney allograft recipients from Expanded Criteria Donors (ECD) under conditions of routine clinical practice. The primary objective is to identify the current criteria/reasons to use sirolimus as base therapy in this selected population and define and understand the emerging patterns of immunosuppressive treatment with sirolimus.
Detailed description
pilot study
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sirolimus | Non interventional. Sirolimus administered by Principal Investigator per standard practice and labeling. |
Timeline
- Start date
- 2008-05-01
- Primary completion
- 2012-12-01
- Completion
- 2012-12-01
- First posted
- 2008-06-13
- Last updated
- 2014-01-22
- Results posted
- 2014-01-22
Locations
8 sites across 1 country: Argentina
Source: ClinicalTrials.gov record NCT00697112. Inclusion in this directory is not an endorsement.